Bristol Myers Squibb buys San Diego cancer therapy company for $4.8B
It's unclear what the Bristol Myers Squibb deal with San Diego's Mirati Therapeutics means for the local workforce.
Source: sandiegouniontribune.com
📰 Charles Baum News
Page 2 - Charles Baum News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Charles Baum. Real-time updates on events, politics, business and more.
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® , a...
Source: marketscreener.com
3 Under-the-Radar Biotech Stocks to Buy in 2023
All three biotech companies focus on oncology therapies.
United States Charles Baum Sanofi Tzield Merck Keytruda American Cancer Society Deciphera Pharmaceuticals
Source: fool.com
Why Shares of Mirati Therapeutics Are Jumping Wednesday
The company replaced its CEO and reported strong revenue growth.
Source: fool.com
Premium Times Publisher joins Poynter Media Transformation Challenge as first African Fellow
The fellowship, Mr Olorunyomi said "looks potentially helpful for the future we seek to plot at the Premium Times and Centre for Journalism..
Source: premiumtimesng.com
Why Shares of Mirati Therapeutics Fell Tuesday
Investors and analysts were unimpressed by trial results on the company's combination therapy to treat non-small cell lung cancer.
Source: fool.com
Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study
/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that based on the results of an interim...
Charles Baum Exchange Commission Prnewswire Mirati Therapeutics Inc Bristol Myers Squibb Company Mirati Therapeutics Inc Evaluating Investigational Sitravatinib
Source: prnewswire.com
Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of...
Source: prnewswire.com
Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of...
Source: prnewswire.com